FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002217631> ?p ?o ?g. }

• W2002217631 endingPage "516" @default.
• W2002217631 startingPage "509" @default.
• W2002217631 abstract "To investigate the efficacy and safety of targeted delivery of autologous bone marrow mononuclear cells (BMMCs), which are highly enriched with mesenchymal stem cells (BMMSCs), via medial circumflex femoral artery in the treatment of osteonecrosis of the femoral head (ONFH).62 patients (78 hips) with ONFH were recruited in this study. All of these patients were treated with BMMCs perfusion via medial circumflex femoral artery. The concentrated BMMCs (30-60ml) were gained from autologous bone marrow (100-200ml) harvested from anterior iliac crest and then were intra-arterially perfused into the femoral head. Ficat stage was used to classify the radiological stage of ONFH. Harris hip score was used to evaluate the clinical symptoms of osteonecrosis. Ficat stage and Harris hip scores were assessed at onset of treatment at 6, 12, 24, 36, 48 and 60months after the initial treatment. Total hip arthroplasty (THA) was also assessed as an endpoint at each follow-up.A follow-up on the patient was done at the end of five years, and 92.31% (72 of 78) of hips achieved a satisfactory clinical result while only 6 hips (7.69%) progressed to clinical failure and required THA. Radiological progression was noted in 34 of 78 hips (43.59%); the overall rate of collapse was 38.24% (26 of 68 hips) in stage-I and stage-II hip combinations and 12.5% (2 of 16) in stage-I hips and 46.15% (24 of 52) in stage-II hips. The mean time of conversion to THA was 3years (1 to 5years) and the average time to collapse were 3.5years (1-5years). The mean Harris hip score increased from 59 points at baseline to 75 points at 12months, 82 points at 24months, 81 points at 36months, 79 points at 48months and 74 points at 60months. Five years after the treatment, 3 of 10 hips (30%) in stage-III had deteriorated to clinical failure whereas only 3 of 68 hips (4.41%) in stage-I and II combination had progressed to clinical failure (p<0.05). Kaplan-Meier survival analysis showed a significant difference in the time to failure between the pre-collapse hips (Ficat stage-I and II) and the post-collapse hips (Ficat stage-III) at five years follow-up (Log-rank test; p<0.01). No complication was found in any patients.Autologous BMMSC perfusion via the medial circumflex femoral artery can relieve symptoms, improve hip function and delay the progression of ONFH. The clinical outcome is better when it is applied prior to the collapse. This work demonstrates that autologous BMMSC perfusion via the medial circumflex femoral artery is a safe, effective and minimally invasive treatment strategy for early-stage ONFH." @default.
• W2002217631 created "2016-06-24" @default.
• W2002217631 creator A5008242142 @default.
• W2002217631 creator A5023872965 @default.
• W2002217631 creator A5031574868 @default.
• W2002217631 creator A5032079976 @default.
• W2002217631 creator A5036566273 @default.
• W2002217631 creator A5065265105 @default.
• W2002217631 date "2013-12-01" @default.
• W2002217631 modified "2023-10-08" @default.
• W2002217631 title "The efficacy of targeted intraarterial delivery of concentrated autologous bone marrow containing mononuclear cells in the treatment of osteonecrosis of the femoral head: A five year follow-up study" @default.
• W2002217631 cites W1911445707 @default.
• W2002217631 cites W1955062584 @default.
• W2002217631 cites W1965425745 @default.
• W2002217631 cites W1974371787 @default.
• W2002217631 cites W1977381921 @default.
• W2002217631 cites W1979729523 @default.
• W2002217631 cites W2003456865 @default.
• W2002217631 cites W2003745782 @default.
• W2002217631 cites W2006921908 @default.
• W2002217631 cites W2024998108 @default.
• W2002217631 cites W2026622347 @default.
• W2002217631 cites W2027016517 @default.
• W2002217631 cites W2029622887 @default.
• W2002217631 cites W2030413258 @default.
• W2002217631 cites W2032507355 @default.
• W2002217631 cites W2034027092 @default.
• W2002217631 cites W2041064440 @default.
• W2002217631 cites W2045256491 @default.
• W2002217631 cites W2058594923 @default.
• W2002217631 cites W2061471986 @default.
• W2002217631 cites W2065932623 @default.
• W2002217631 cites W2069160495 @default.
• W2002217631 cites W2074510736 @default.
• W2002217631 cites W2082861980 @default.
• W2002217631 cites W2083826849 @default.
• W2002217631 cites W2085117762 @default.
• W2002217631 cites W2088964957 @default.
• W2002217631 cites W2090553057 @default.
• W2002217631 cites W2104813838 @default.
• W2002217631 cites W2120377232 @default.
• W2002217631 cites W2130531691 @default.
• W2002217631 cites W2156750988 @default.
• W2002217631 cites W2156969855 @default.
• W2002217631 cites W2167929640 @default.
• W2002217631 cites W2181932044 @default.
• W2002217631 cites W2197697535 @default.
• W2002217631 doi "https://doi.org/10.1016/j.bone.2013.08.022" @default.
• W2002217631 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3927161" @default.
• W2002217631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23994171" @default.
• W2002217631 hasPublicationYear "2013" @default.
• W2002217631 type Work @default.
• W2002217631 sameAs 2002217631 @default.
• W2002217631 citedByCount "59" @default.
• W2002217631 countsByYear W20022176312014 @default.
• W2002217631 countsByYear W20022176312015 @default.
• W2002217631 countsByYear W20022176312016 @default.
• W2002217631 countsByYear W20022176312017 @default.
• W2002217631 countsByYear W20022176312018 @default.
• W2002217631 countsByYear W20022176312019 @default.
• W2002217631 countsByYear W20022176312020 @default.
• W2002217631 countsByYear W20022176312021 @default.
• W2002217631 countsByYear W20022176312022 @default.
• W2002217631 countsByYear W20022176312023 @default.
• W2002217631 crossrefType "journal-article" @default.
• W2002217631 hasAuthorship W2002217631A5008242142 @default.
• W2002217631 hasAuthorship W2002217631A5023872965 @default.
• W2002217631 hasAuthorship W2002217631A5031574868 @default.
• W2002217631 hasAuthorship W2002217631A5032079976 @default.
• W2002217631 hasAuthorship W2002217631A5036566273 @default.
• W2002217631 hasAuthorship W2002217631A5065265105 @default.
• W2002217631 hasBestOaLocation W20022176312 @default.
• W2002217631 hasConcept C126322002 @default.
• W2002217631 hasConcept C141071460 @default.
• W2002217631 hasConcept C146357865 @default.
• W2002217631 hasConcept C151730666 @default.
• W2002217631 hasConcept C197321550 @default.
• W2002217631 hasConcept C2776211809 @default.
• W2002217631 hasConcept C2776820930 @default.
• W2002217631 hasConcept C2778336525 @default.
• W2002217631 hasConcept C2779079599 @default.
• W2002217631 hasConcept C2779100257 @default.
• W2002217631 hasConcept C2780007613 @default.
• W2002217631 hasConcept C71924100 @default.
• W2002217631 hasConcept C86803240 @default.
• W2002217631 hasConceptScore W2002217631C126322002 @default.
• W2002217631 hasConceptScore W2002217631C141071460 @default.
• W2002217631 hasConceptScore W2002217631C146357865 @default.
• W2002217631 hasConceptScore W2002217631C151730666 @default.
• W2002217631 hasConceptScore W2002217631C197321550 @default.
• W2002217631 hasConceptScore W2002217631C2776211809 @default.
• W2002217631 hasConceptScore W2002217631C2776820930 @default.
• W2002217631 hasConceptScore W2002217631C2778336525 @default.
• W2002217631 hasConceptScore W2002217631C2779079599 @default.
• W2002217631 hasConceptScore W2002217631C2779100257 @default.
• W2002217631 hasConceptScore W2002217631C2780007613 @default.
• W2002217631 hasConceptScore W2002217631C71924100 @default.
• W2002217631 hasConceptScore W2002217631C86803240 @default.

• next